Company profile: Bugworks Research
1.1 - Company Overview
Company description
- Provider of drug discovery focused on combating antimicrobial resistance (AMR) and small molecule cancer therapeutics, including BWC2094 targeting the adenosine pathway (CRC, NSCLC, TNBC, pancreas, prostate, RCC, HNSCC); ATM/DNA-PK dual inhibitors (BWC5036/BWC5089); BWC5044/BWC5077, BWC4496; spliceosome modulators/DNA damage agents; and ADC payload opportunities.
Products and services
- BWC2094: Small-molecule, Adenosine-pathway therapeutic architected to target the Adenosine pathway, with potential applications in CRC, NSCLC, TNBC, pancreas, prostate, RCC, and HNSCC
- BWC5036/BWC5089: Dual-target ATM/DNA-PK inhibitors engineered to simultaneously inhibit ATM and DNA-PK, aimed at treating recalcitrant tumors
- Spliceosome Modulators/DNA Damage: Mechanism-directed small molecules developed to target spliceosome modulation and DNA damage for treating recalcitrant tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bugworks Research
Pardes Bio
HQ: United States
Website
- Description: Provider of direct-acting antivirals for the treatment of coronavirus, applying modern reversible-covalent chemistry to discover and develop novel oral drug candidates starting with COVID-19, as a clinical-stage biopharmaceutical company focused on improving patient access to these medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pardes Bio company profile →
Biocure Technology
HQ: Canada
Website
- Description: Provider of biosimilars and CAR-T cell pharmaceutical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocure Technology company profile →
Spero Therapeutics
HQ: United States
Website
- Description: Provider of oral and IV antibiotic therapies for gram-negative infections: Tebipenem HBr for complicated urinary tract infections and acute pyelonephritis to reduce hospitalizations and support transition from IV to home care; SPR720, an oral investigational agent for nontuberculous mycobacterial pulmonary disease; and SPR206, an IV candidate for multidrug-resistant Gram-negative infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spero Therapeutics company profile →
Spectrum Antimicrobials
HQ: United States
Website
- Description: Provider of pharmaceutical drug development specializing in antibiotics and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectrum Antimicrobials company profile →
SOM Biotech
HQ: Spain
Website
- Description: Provider of AI-based drug discovery and drug repurposing for orphan CNS diseases via the SOM AI PRO platform, validated by two successful Phase 2 trials (TTR amyloidosis; chorea in Huntington’s). Pipeline includes SOM3355 (oral VMAT2 inhibitor, Phase 2b), SOM0226 (TTR stabilizer, outlicensed), SOM1311 (PKU chaperone, expected to enter Phase 2a in 2024), and SOM0034 (DMD program, Phase 2 expected 2025).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SOM Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bugworks Research
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bugworks Research
2.2 - Growth funds investing in similar companies to Bugworks Research
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bugworks Research
4.2 - Public trading comparable groups for Bugworks Research
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →